Skip to main content

RxNews®

Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.

Jubbonti® (denosumab-bbdz) – New first-time interchangeable biosimilar approval

March 5, 2024 - The FDA approved Sandoz’s Jubbonti (denosumab-bbdz), biosimilar and interchangeable to Amgen’s Prolia® (denosumab).

Download PDF

Rx navigation